Page 39 - Alimera Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: New York, March 11, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Advanced Ophthalmology Technologies Market Research Report by Type, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06034082/?utm_source=GNW Market Statistics: The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available. 1. The Global Advanced Ophthalmology Technologies Market is expect...

Gainers Savara (NASDAQ:SVRA) stock increased by 16.75% to $2.09 during Wednesday's after-market session. Trading volume for this security closed at ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for ... Alimera Sciences, Inc.February 18, 2021 GMT ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that ILUVIEN is now available in Finland for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (...

ResearchAndMarkets.com’s offering. The global anterior uveitis treatment market is projected to witness considerable growth during the forecast period. The major factors contributing to the growth of the market include the increasing prevalence of anterior uveitis due to the rising incidence of optical infections. In addition, the rising medical tourism and an expected approval for products under clinical trial and development is further estimated to propel the market growth during the forecast period. The anterior uveitis treatment market is classified on the basis of therapeutics into cor...

SWK Holdings Provides Portfolio Update Highlighting Recent Achievements Specialty Finance Portfolio Growth, Underlying Credit Performance Highlight Strong 2020 Closed Four Transactions During 2020, Deploying $35 Million Two Milestone Payments Received from Cara Therapeutics Related to the Development of Oral KORSUVA™ Fourth Quarter and Full-Year 2020 Financial Results Expected in March 2021 News provided by Share this article Share this article DALLAS, Feb. 16, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small ...